The stock of Geron Corporation (NASDAQ:GERN) is a huge mover today! About 1.31M shares traded hands. Geron Corporation (NASDAQ:GERN) has declined 12.70% since February 26, 2016 and is downtrending. It has underperformed by 23.12% the S&P500.
The move comes after 7 months positive chart setup for the $348.56 million company. It was reported on Oct, 1 by Barchart.com. We have $6.94 PT which if reached, will make NASDAQ:GERN worth $676.21M more.
Analysts await Geron Corporation (NASDAQ:GERN) to report earnings on November, 3. They expect $-0.06 earnings per share, down 135.29% or $0.23 from last year’s $0.17 per share. After $-0.05 actual earnings per share reported by Geron Corporation for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.
Geron Corporation (NASDAQ:GERN) Ratings Coverage
Out of 2 analysts covering Geron (NASDAQ:GERN), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Geron has been the topic of 4 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Zacks given on Saturday, August 8. FBR Capital maintained the shares of GERN in a report on Tuesday, September 13 with “Outperform” rating. The firm has “Overweight” rating by Piper Jaffray given on Monday, December 7. The rating was maintained by MLV on Monday, August 10 with “Buy”.
According to Zacks Investment Research, “Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.”
Insitutional Activity: The institutional sentiment decreased to 0.6 in 2016 Q2. Its down 0.79, from 1.39 in 2016Q1. The ratio worsened, as 16 funds sold all Geron Corporation shares owned while 44 reduced positions. 8 funds bought stakes while 28 increased positions. They now own 61.08 million shares or 8.99% less from 67.11 million shares in 2016Q1.
Glenmede Trust Na accumulated 1,100 shares or 0% of the stock. Credit Suisse Ag has 196,172 shares for 0% of their US portfolio. The Virginia-based Virginia Retirement Et Al has invested 0% in Geron Corporation (NASDAQ:GERN). The New York-based Gotham Asset Limited Liability Corporation has invested 0% in Geron Corporation (NASDAQ:GERN). State Of New Jersey Common Pension Fund D holds 0.01% of its portfolio in Geron Corporation (NASDAQ:GERN) for 870,000 shares. Lpl Fin Ltd Liability Corporation holds 0% of its portfolio in Geron Corporation (NASDAQ:GERN) for 15,125 shares. Prudential Financial owns 12,817 shares or 0% of their US portfolio. Moreover, Renaissance Technologies Limited Liability Company has 0% invested in Geron Corporation (NASDAQ:GERN) for 461,580 shares. Tiaa Cref Investment Limited Liability Company accumulated 0% or 460,988 shares. Moreover, Jpmorgan Chase has 0% invested in Geron Corporation (NASDAQ:GERN) for 37,627 shares. Tudor Et Al has 88,300 shares for 0.01% of their US portfolio. Pnc Financial Ser Grp holds 0% or 4,893 shares in its portfolio. The United Kingdom-based Blackrock Group Limited has invested 0% in Geron Corporation (NASDAQ:GERN). Voya Investment Limited Liability Com has 0% invested in the company for 70,915 shares. Proshare Advsr Limited Liability last reported 136,799 shares in the company.
More news for Geron Corporation (NASDAQ:GERN) were recently published by: Fool.com, which released: “Why Geron Corporation Is Plunging Today” on September 12, 2016. Streetinsider.com‘s article titled: “Geron Corp (GERN), Janssen Pharma Enter Exclusive Licensing Agreement” and published on September 19, 2016 is yet another important article.
GERN Company Profile
Geron Corporation (Geron), incorporated on November 28, 1990, is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Firm operates through the segment, which includes discovery and development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that focuses and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.